Stocktoria
OmniAb, Inc. OABI
OmniAb, Inc. (OABI) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $18.7M at a -347.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.163 |
| Retained earnings / assets | -0.552 |
| EBIT / assets | -0.229 |
| Equity / liabilities | 7.88 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OABI | OmniAb, Inc. | 1/9 | 6 | — | -29.3% |
| BIAF | bioAffinity Technologies, Inc. | 3/9 | — | — | — |
| ABSI | Absci Corp | 2/9 | -1.9 | — | — |
| ISPC | iSpecimen Inc. | 3/9 | — | — | — |
| ONMD | OneMedNet Corp | 5/9 | — | — | — |
| VSBC | VITASPRING BIOMEDICAL CO. LTD. | 4/9 | — | — | — |
| NRC | NRC HEALTH | 3/9 | 0.03 | — | -4% |
About OmniAb, Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
FAQ
Is OABI financially healthy?
OmniAb, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does OABI pay a dividend?
No, OmniAb, Inc. does not currently pay a dividend.
How profitable is OABI?
In FY2025, OmniAb, Inc. had a net margin of -347.0% and a return on equity of -24.3%.
What is the analyst price target for OABI?
The average Wall-Street price target for OmniAb, Inc. is $7.33, about 114.4% above the recent price, from 6 analysts.
Is OABI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on OmniAb, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.